InDex Pharmaceuticals Holding AB (publ)

OM:INDEX Stock Report

Market Cap: SEK 286.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

InDex Pharmaceuticals Holding Valuation

Is INDEX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INDEX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate INDEX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate INDEX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INDEX?

Key metric: As INDEX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for INDEX. This is calculated by dividing INDEX's market cap by their current revenue.
What is INDEX's PS Ratio?
PS Ratio2.7x
SalesSEK 108.34m
Market CapSEK 286.59m

Price to Sales Ratio vs Peers

How does INDEX's PS Ratio compare to its peers?

The above table shows the PS ratio for INDEX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.9x
ODI ODI Pharma
1.5xn/aSEK 32.3m
ZICC Ziccum
1.3xn/aSEK 7.6m
CLBIO Corline Biomedical
8.1x46.0%SEK 190.4m
ACUC AcuCort
12.9xn/aSEK 90.3m
INDEX InDex Pharmaceuticals Holding
2.7xn/aSEK 286.6m

Price-To-Sales vs Peers: INDEX is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (9.3x).

Price to Sales Ratio vs Industry

How does INDEX's PS Ratio compare vs other companies in the SE Pharmaceuticals Industry?

12 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.12.9x31.7%
INDEX InDex Pharmaceuticals Holding
 2.7xn/aUS$27.34m
KARO Karo Pharma
4.8xn/aUS$1.59b
SECARE Swedencare
3.1x12.0%US$701.03m
INDEX 2.7xIndustry Avg. 12.9xNo. of Companies12PS020406080100+
12 CompaniesEstimated GrowthMarket Cap
Industry Avg.12.9x75.4%
INDEX InDex Pharmaceuticals Holding
 2.7x-48.5%US$27.34m
No more companies

Price-To-Sales vs Industry: INDEX is good value based on its Price-To-Sales Ratio (2.7x) compared to the Swedish Pharmaceuticals industry average (11.4x).

Price to Sales Ratio vs Fair Ratio

What is INDEX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INDEX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate INDEX's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst INDEX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
SEK 0.54
0%
49.5%SEK 0.80SEK 0.27n/a2
Dec ’25n/a
SEK 0.54
0%
49.5%SEK 0.80SEK 0.27n/a2
Nov ’25n/a
SEK 0.54
0%
49.5%SEK 0.80SEK 0.27n/a2
Oct ’25n/a
SEK 0.54
0%
49.5%SEK 0.80SEK 0.27n/a2
Sep ’25n/a
SEK 0.54
0%
49.5%SEK 0.80SEK 0.27n/a2
Aug ’25n/a
SEK 0.54
0%
49.5%SEK 0.80SEK 0.27n/a2
Jul ’25n/a
SEK 0.54
0%
49.5%SEK 0.80SEK 0.27n/a2
Jun ’25SEK 0.53
SEK 0.54
+1.3%
49.5%SEK 0.80SEK 0.27n/a2
May ’25SEK 0.39
SEK 0.54
+35.8%
49.5%SEK 0.80SEK 0.27n/a2
Apr ’25SEK 0.29
SEK 0.54
+83.2%
49.5%SEK 0.80SEK 0.27n/a2
Mar ’25SEK 0.28
SEK 0.54
+89.0%
49.5%SEK 0.80SEK 0.27n/a2
Feb ’25SEK 0.24
SEK 0.56
+133.2%
44.1%SEK 0.80SEK 0.31n/a2
Jan ’25SEK 0.26
SEK 0.56
+116.8%
44.1%SEK 0.80SEK 0.31n/a2
Dec ’24SEK 0.24
SEK 0.56
+128.4%
44.1%SEK 0.80SEK 0.31n/a2
Nov ’24SEK 0.75
SEK 1.40
+87.2%
42.9%SEK 2.00SEK 0.80n/a2
Oct ’24SEK 0.80
SEK 1.40
+75.0%
42.9%SEK 2.00SEK 0.80n/a2
Sep ’24SEK 0.85
SEK 1.40
+65.5%
42.9%SEK 2.00SEK 0.80n/a2
Aug ’24SEK 0.61
SEK 1.30
+113.1%
38.5%SEK 1.80SEK 0.80n/a2
Jul ’24SEK 0.53
SEK 1.30
+145.3%
38.5%SEK 1.80SEK 0.80n/a2
Jun ’24SEK 0.57
SEK 1.30
+127.3%
38.5%SEK 1.80SEK 0.80SEK 0.532
May ’24SEK 0.40
SEK 1.30
+229.1%
38.5%SEK 1.80SEK 0.80SEK 0.392
Apr ’24SEK 0.38
SEK 1.30
+242.6%
38.5%SEK 1.80SEK 0.80SEK 0.292
Mar ’24SEK 0.41
SEK 1.90
+364.5%
5.3%SEK 2.00SEK 1.80SEK 0.282
Feb ’24SEK 0.46
SEK 2.75
+498.5%
27.3%SEK 3.50SEK 2.00SEK 0.242
Jan ’24SEK 0.84
SEK 2.75
+225.4%
27.3%SEK 3.50SEK 2.00SEK 0.262
Dec ’23SEK 0.93
SEK 2.75
+197.3%
27.3%SEK 3.50SEK 2.00SEK 0.242

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/10 20:28
End of Day Share Price 2024/06/10 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

InDex Pharmaceuticals Holding AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arvid NecanderCarnegie Investment Bank AB
Filip EinarssonRedeye